Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico

HIV Medicine

Volumn 6, Issue 6, 2005, Pages 403-409

  Escoto Delgadillo, M ^a   Vázquez Valls, Eduardo ^a   Ramirez Rodriguez M ^a   Corona Nakamura, A ^a   Amaya Tapia, G ^b   Quintero Perez N ^c   Panduro Cerda, A ^d,e   Torrez Mendoza, B M ^e  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b West General Hospital   (Mexico)

^c Dr Juan I Menchaca Civil Hospital of Guadalajara   (Mexico)

^d HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^e UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Antiretroviral na ve patients; HIV drug resistance; Resistance codons

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEXICO; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 28444435435     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00326.x     Document Type: Article

References (27)

1. Jorgensen LB, Chistensen MB, Gerstoft J et al. Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark. Scand J Infect Dis 2003; 35: 800-807.
2. Fournier S, Chaffaut C, Maillard A et al. Factor associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study. HIV Med 2005; 6: 129-134.
3. Douglas DR. Benefits and limitations of testing for resistance to HIV drugs. J Antimicrob Chemother 2004; 53: 555-557.
4. Clavel F, Hance AJ. Medical progress: HIV drug resistance. N Engl J Med 2004; 350: 1023-1035.
5. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004; 53: 696-699.
6. Aceti A. Genotipic resistance test in the management of the HIV-infected patient at virological failure. Scand J Infect Dis 2003; 35 (Suppl. 106): 61-104.
7. Turner D, Brenner B, Routy JP et al. Diminished representation of HIV-1 variants containing select drug resistance conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37: 1627-1631.
8. Lazzari S, Felici A, Sobel H, Bertagnolio S. HIV drug resistance surveillance: summary of an April 2003 WHO consultation. AIDS 2004; 18: S49-S53.
9. Girardi E. Epidemiological aspects of transmitted HIV-1 drug resistance. Scand J Infect Dis 2003; 35 (Suppl. 106): 17-20.
10. Chainx ML, Descamps D, Harzic M et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 2003; 17: 2635-2643.
11. Brideiro RM, Diaz RS, Sabino EC et al. Brazilian network for HIV drug resistance surveillance (HIV-BresNet): a survey of chronically infected individuals. AIDS 2003; 17: 1063-1069.
12. Soares MA, Brideiro RM, Tanuri A. Primary HIV-1 drug resistance in Brazil. AIDS 2004; 18: S9-S13.
13. Weinstock HS, Zaidi I, Heneine W et al. The epidemiology of antiretroviral drug resistance among drug naïve HIV-1 infected persons in 10 US cities. J Infect Dis 2004; 189: 2174-2180.
14. Derdelinckx I, Van Laethem K, Maes B et al. Current levels of drug resistance among therapy naïve HIV infected patients have significant impact on treatment response. J Acquir Immune Defic Syndr 2004; 37: 1664-1666.
15. Kuritzkes DR. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDs 2004; 18: 259-273.
16. Liuzzi G. Genotipic resistance test for the management of the patients failing highly active antiretroviral therapy: the resistance pattern in different biological compartments. Scand J Infect Dis 2003; 35 (Suppl. 106): 90-93.
17. Hirsc MS, Brun-Vézinet F, Clotet B et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an international AIDS society-USA panel. HIV/AIDS 2003; 37: 113-128.
18. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001; 15: 309-320.
19. International AIDS Society, USA. Special contribution: Drug resistance mutations. Topics HIV Med 2004; 12: 119-124.
20. Torti C, Bono L, Gargiulo F. Prevalence of drug resistance and newly recognised treatment related substitution in the HIV-1 reverse transcriptase and protease from HIV-positive patients naïve for anti-retrovirals. Clin Microbiol Infect 2004; 10: 826-830.
21. Roge BT, Katzenstein TL, Nielsen HL, Gerstoft J. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease failure on nelfinavir-containing HAART. HIV Med 2003; 4: 38-47.
22. Shafer RW. Genotypic Testing for HIV-1 Drug Resistance. http://hivdb.stanford.edu/pages/gartTesting.html 2004.
23. Stanford University 2004. HIV Drug Resistance Database. Comments HIVdb. Drug Resistance Algorithm (Beta Test), Version 3.9. http://hivdb6.stanford.edu/asi/deployed/hiv_central.pl?program=hivdb.
24. Alexander CS, Dong W, Chan K et al. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS 2001; 15: 601-607.
25. Harrigan PR, Montaner SGJ, Wegner AS et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15: 1671-1677.
26. Tuner B, Brenner B, Wainberg AM. Relationships among nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1. J Antimicrob Chemother 2004; 53: 53-57.
27. Dorz S, Lazzarini L, Cattelan A et al. Evaluation of adherence to antiretroviral therapy in Italian HIV patients. AIDS Patient Care STDs 2003; 17: 33-41.